Interestingly, IL-17 significantly contributes to the major comorbidity of NAFLD, specifically early atherosclerosis, which was confirmed in a study involving obese NAFLD patients (Tarantino et al., 2014). The gene discussed is IL17A; the disease is metabolic dysfunction-associated steatotic liver disease.